646 results on '"Polli, James E."'
Search Results
2. Bioavailability and Bioequivalence
3. Application of Advanced Modeling Approaches Supporting Generic Product Development Under GDUFA for Fiscal Year 2023
4. In Vitro Lipolysis Model to Predict Food Effect of Poorly Water-Soluble Drugs Itraconazole, Rivaroxaban, and Ritonavir
5. Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability
6. Efficiency of single pharmaceutical surfactants to mimic intestinal biorelevant media solubilization and dissolution of etravirine: Comparison of intrinsic and film dissolution models
7. Application of bootstrap f2 to dissolution data from biorelevant media and evidence of the conservative nature of bootstrap f2
8. Concordance of vacuum compression molding with spray drying in screening of amorphous solid dispersions of itraconazole
9. Drug Dissolution in Oral Drug Absorption: Workshop Report
10. Validation of a method for itraconazole and major metabolite hydroxyitraconazole for LC-MS/MS analysis with application in a formulation clinical study
11. Dissolution-Hollow Fiber Membrane (D-HFM) System to Anticipate Biopharmaceutics Risk of Tablets and Capsules
12. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate
13. A robust, viable, and resource sparing HPLC-based logP method applied to common drugs
14. Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans
15. A Simple One-Parameter Percent Dissolved Versus Time Dissolution Equation that Accommodates Sink and Non-sink Conditions via Drug Solubility and Dissolution Volume
16. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine
17. Enteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum
18. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report
19. Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes
20. Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity
21. Sources of dissolution variability into biorelevant media
22. Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy
23. Research and Education Needs for Complex Generics
24. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine
25. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report
26. Evaluation of Excipient Risk in BCS Class I and III Biowaivers
27. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy
28. Virtual Issue Honoring Gordon L. Amidon: First Editor-in-Chief of Molecular Pharmaceutics
29. Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring
30. Bioavailability and Bioequivalence
31. Challenges in Permeability Assessment for Oral Drug Product Development
32. Challenges in Permeability Assessment for Oral Drug Product Development
33. Drug Dissolution in Oral Drug Absorption:Workshop Report
34. Characterization of Grades of HPMCAS Spray Dried Dispersions of Itraconazole Based on Supersaturation Kinetics and Molecular Interactions Impacting Formulation Performance
35. Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy
36. Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions
37. Authorized Generic Drugs: an Overview
38. Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview
39. Novel nitroxide-bile acid conjugates inform substrate requirements for human bile acid transporters
40. Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs
41. Reply to “On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs”
42. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin
43. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir
44. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2)
45. Synthesis and Evaluation of Bile Acid–Ribavirin Conjugates as Prodrugs to Target the Liver
46. Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
47. A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide
48. Biowaiver monograph for immediate-release dosage Forms: Levamisole hydrochloride
49. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Levocetirizine Dihydrochloride
50. A Simple One-Parameter Percent Dissolved Versus Time Dissolution Equation that Accommodates Sink and Non-sink Conditions via Drug Solubility and Dissolution Volume
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.